- Home
- OTLK vs WGRX Comparison
OTLK vs WGRX Comparison
Compare OTLK & WGRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OTLK
- WGRX
- Stock Information
- Founded
- OTLK 2010
- WGRX 2022
- Country
- OTLK United States
- WGRX United States
- Employees
- OTLK N/A
- WGRX N/A
- Industry
- OTLK Biotechnology: Biological Products (No Diagnostic Substances)
- WGRX Other Pharmaceuticals
- Sector
- OTLK Health Care
- WGRX Health Care
- Exchange
- OTLK Nasdaq
- WGRX Nasdaq
- Market Cap
- OTLK 42.8M
- WGRX 43.9M
- IPO Year
- OTLK 2016
- WGRX 2025
- Fundamental
- Price
- OTLK $1.21
- WGRX $0.64
- Analyst Decision
- OTLK Buy
- WGRX
- Analyst Count
- OTLK 5
- WGRX 0
- Target Price
- OTLK $5.25
- WGRX N/A
- AVG Volume (30 Days)
- OTLK 1.4M
- WGRX 41.9M
- Earning Date
- OTLK 08-14-2025
- WGRX 11-19-2025
- Dividend Yield
- OTLK N/A
- WGRX N/A
- EPS Growth
- OTLK N/A
- WGRX N/A
- EPS
- OTLK N/A
- WGRX N/A
- Revenue
- OTLK $1,505,322.00
- WGRX $36,738,599.00
- Revenue This Year
- OTLK N/A
- WGRX N/A
- Revenue Next Year
- OTLK $342.80
- WGRX N/A
- P/E Ratio
- OTLK N/A
- WGRX N/A
- Revenue Growth
- OTLK N/A
- WGRX 82384.51
- 52 Week Low
- OTLK $0.79
- WGRX $0.34
- 52 Week High
- OTLK $6.98
- WGRX $7.04
- Technical
- Relative Strength Index (RSI)
- OTLK 45.22
- WGRX 46.63
- Support Level
- OTLK $1.28
- WGRX $0.55
- Resistance Level
- OTLK $1.31
- WGRX $0.82
- Average True Range (ATR)
- OTLK 0.09
- WGRX 0.14
- MACD
- OTLK -0.01
- WGRX 0.03
- Stochastic Oscillator
- OTLK 0.00
- WGRX 26.89
About OTLK Outlook Therapeutics Inc.
Outlook Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.
About WGRX Wellgistics Health Inc. Common Stock
Wellgistics Health Inc is a healthcare technology and pharmaceutical logistics company. It simplifies the logistics of prescription fulfillment from the manufacturer and provider to the patient. It is focused on improving the lives of patients while delivering unique solutions for pharmacies, providers, pharmaceutical manufacturers, and payors.